Biosensors International Group has announced a distribution agreement with Veryan Medical Ltd. for BioMimics 3D, a nitinol stent with three-dimensional helical geometry designed for use in the superficial femoral artery.
ECRI Institute has created a report that offers an overview of drug-eluting balloon (DEB) technology, “Health Technology Forecast report, "Drug-eluting Angioplasty Balloons for Preventing Restenosis after Revascularization." The report details some of the key questions regarding DEBs.
SynCardia Systems Inc. has received U.S. Food and Drug Administration (FDA) approval to conduct a clinical study of the effectiveness of the SynCardia temporary Total Artificial Heart for permanent use, also called destination therapy.
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
The U.S. Food and Drug Administration (FDA) has approved for human evaluation a nanoparticle-based imaging agent jointly developed at Washington University School of Medicine in St. Louis and the University of California, Santa Barbara, in collaboration with Texas A&M University.
Medtronic announced new results from the PainFree SST and Shock-Less clinical studies published in the journal HeartRhythm.
Merge Healthcare Inc. announced that Merge Cardio has been named Best in KLAS for the cardiology software category in the "2014 Best in KLAS: Software & Services" report. In addition, Merge Hemo has been named the KLAS Category Leader in Cardiology Hemodynamics. This marks the second and fourth consecutive wins for Merge Cardio and Merge Hemo, respectively.
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
The 2014 Best in KLAS report ranks healthcare vendors and their solutions by the professionals who use them—healthcare providers.
There are several new interventional and minimally invasive surgical heart failure (HF) devices in development or in trials that might offer new ways to boost patient volume in the coming years. There is a lot of potential economic opportunity in new HF therapies, since HF represents the single-largest cause of hospitalizations in many countries and it is the largest expense in the U.S. Medicare budget.
Medtronic revealed new one-year clinical data showing that transcatheter aortic valve replacement (TAVR) with the self-expanding CoreValve System offers advantages in survival and safety compared to surgical aortic valve replacement (SAVR) in high risk aortic stenosis patients who have previously undergone coronary artery bypass grafting (CABG) surgery.
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
St. Jude Medical Inc. announced U.S. Food and Drug Administration (FDA) approval of the FlexAbility Ablation Catheter, a new ablation technology used by electrophysiologists for the treatment of cardiac arrhythmias.
The Diagnostics Division of Siemens Healthcare unveiled its latest point-of-care acute care analyzer for the management of patients with cardiovascular disease symptoms at Medlab in Arab Health 2015, Dubai, Jan. 26-29. The company’s Stratus CS 200 Acute Care Diagnostic System is designed to enhance simple operation and instrument management at the point of care to help facilitate rapid decision-making and optimal patient care.
A tool designed to assess what interferes with acute heart failure patients' ability to care for themselves after hospital discharge holds promise for improving patient outcomes and reducing readmissions to the hospital. The patient survey, designed by researchers at Vanderbilt University, was published online in Annals of Emergency Medicine, along with patient responses that shed light on the non-medical issues that limit patients' ability to care for themselves.
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
Neovasc Inc. has commenced a public offering in the United States of 8 million shares of the company to raise money for upcoming U.S. clinical trials and development of its transcatheter mitral valve and treatment system for refractory angina.
Maquet Medical Systems USA announced an agreement to serve as the exclusive U.S. distributor of InterValve Inc.'s V8 Aortic Valvuloplasty Balloon Catheter.
Abiomed Inc. said the Impella RP (Right Percutaneous) system has received U.S. Food and Drug Administration (FDA) approval under a humanitarian device exemption (HDE). This is the first percutaneous single access heart pump designed for right heart support to receive FDA approval. Abiomed completed the HDE submission for the Impella RP in September 2014 following the completion of the RECOVER RIGHT study.